Literature DB >> 20384535

Sodium channel blockers for neuropathic pain.

Valentina Zuliani1, Mirko Rivara, Marco Fantini, Gabriele Costantino.   

Abstract

IMPORTANCE OF THE FIELD: The voltage-gated sodium channels (VGSCs) play a fundamental role in controlling cellular excitability and their abnormal activity is related to several pathological processes, including cardiac arrhythmias, epilepsy, neurodegenerative diseases, spasticity, chronic and neuropathic pain. In particular, neuropathic pain (e.g., postherpetic and trigeminal neuralgia, diabetic neuropathy and spinal cord injury) is a serious clinical problem that affects a high percentage of the world population. Because an altered sodium channel isoform expression profile has been considered one reason for the changes in neuronal excitability, there is a continuous quest for new selective molecules targeting sodium channels for the treatment of chronic pain. AREAS COVERED IN THIS REVIEW: PubMed, http://www.sciencedirect.com/ , SciFinder Scholar and http://ep.espacenet.com/ were used as sources for this review and patents between 2007 and September 2009 were taken into account for the sodium channel blockers molecular classes reviewed and discussed herein. WHAT THE READER WILL GAIN: The sodium channel blockers reported in this review have been categorized into different molecular classes on the basis of their wide structural diversity. This classification, somewhat arbitrary, does not necessarily reflect the presence of pharmacophoric elements but offers a useful way to discuss and comment on structurally homogenous classes of chemotypes recently patented. TAKE HOME MESSAGE: The continuous discoveries in the field of sodium channel blockers, highlighted by the increasing numbers of patent applications published in the last few years and by the numbers of compounds currently in clinical development, underline the importance of this target for the treatment of neuropathic pain. The great difficulty in the design of new selective and active structures, not obtained from old VGSC blockers that are often associated with high risk of adverse effects, is a strong challenge for medicinal chemistry research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20384535     DOI: 10.1517/13543771003774118

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN: 1354-3776            Impact factor:   6.674


  13 in total

Review 1.  Targeting voltage-gated sodium channels for treatment for chronic visceral pain.

Authors:  Fei-Hu Qi; You-Lang Zhou; Guang-Yin Xu
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

2.  Mechanism and molecular basis for the sodium channel subtype specificity of µ-conopeptide CnIIIC.

Authors:  René Markgraf; Enrico Leipold; Jana Schirmeyer; Marianne Paolini-Bertrand; Oliver Hartley; Stefan H Heinemann
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

Review 3.  The role of sodium channels in painful diabetic and idiopathic neuropathy.

Authors:  Giuseppe Lauria; Dan Ziegler; Rayaz Malik; Ingemar S J Merkies; Stephen G Waxman; Catharina G Faber
Journal:  Curr Diab Rep       Date:  2014-10       Impact factor: 4.810

4.  Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia.

Authors:  David R Witty; Giuseppe Alvaro; Dominique Derjean; Gerard M P Giblin; Kevin Gunn; Charles Large; David T Macpherson; Valerie Morisset; Davina Owen; Joanne Palmer; Francois Rugiero; Simon Tate; Christopher A Hinckley; Himanshu Naik
Journal:  ACS Med Chem Lett       Date:  2020-07-16       Impact factor: 4.345

5.  Antinociceptive activities of lidocaine and the nav1.8 blocker a803467 in diabetic rats.

Authors:  Tufan Mert; Yasemin Gunes
Journal:  J Am Assoc Lab Anim Sci       Date:  2012       Impact factor: 1.232

6.  Evaluation of the effects of novel nafimidone derivatives on thermal hypoalgesia in mice with diabetic neuropathy.

Authors:  Suat Kamışlı; Arzu Karakurt; Ayşe B Uyumlu; Basri Satılmış; Abdullah Alagöz; Metin F Genç; Kadir Batcıoğlu
Journal:  Balkan Med J       Date:  2013-03-01       Impact factor: 2.021

7.  Identification of sodium channel isoforms that mediate action potential firing in lamina I/II spinal cord neurons.

Authors:  Michael E Hildebrand; Janette Mezeyova; Paula L Smith; Michael W Salter; Elizabeth Tringham; Terrance P Snutch
Journal:  Mol Pain       Date:  2011-09-12       Impact factor: 3.395

8.  Left-shifted nav channels in injured bilayer: primary targets for neuroprotective nav antagonists?

Authors:  Catherine E Morris; Pierre-Alexandre Boucher; Béla Joós
Journal:  Front Pharmacol       Date:  2012-02-23       Impact factor: 5.810

9.  Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis.

Authors:  Lorcan Browne; Katie Lidster; Sarah Al-Izki; Lisa Clutterbuck; Cristina Posada; A W Edith Chan; Dieter Riddall; John Garthwaite; David Baker; David L Selwood
Journal:  J Med Chem       Date:  2014-03-21       Impact factor: 7.446

10.  Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels.

Authors:  Michela De Bellis; Annamaria De Luca; Jean F Desaphy; Roberta Carbonara; Judith A Heiny; Ann Kennedy; Alessia Carocci; Maria M Cavalluzzi; Giovanni Lentini; Carlo Franchini; Diana Conte Camerino
Journal:  Biophys J       Date:  2013-01-22       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.